Critique: Why So Many Guys Are Obsessed With Testosterone - The New York Times

Source: nytimes
Authors: (none listed)
URL: https://www.nytimes.com/2026/05/12/magazine/testosterone-masculinity-trump-rfk.html

What the article reports

The article examines the sharp rise in testosterone replacement therapy (T.R.T.) prescriptions in the United States, tracing the scientific history of the hormone, the Trump administration's explicit embrace of testosterone as a symbol of masculine health, the boom in direct-to-consumer online clinics, and the cultural and psychological forces driving men — with and without clinical deficiency — toward the drug. It draws on interviews with 14 men on T.R.T., several urologists and endocrinologists, and a senior HHS official to assess both the medical evidence and the ideological valence testosterone has acquired.

Factual accuracy — Strong

The piece cites specific, sourced data throughout. The prescription-volume figures ("nearly 12 million prescriptions in 2025, from fewer than 1 million in 2000") are attributed to IQVIA by name. The 2023 randomized trial of 5,200 men is accurately summarized — the article correctly notes it found no difference in cardiovascular events or prostate cancer versus placebo, and accurately notes the F.D.A. removed its warning label in February 2025. The historical claim about the 1941 single-patient prostate-cancer paper is verifiable and contextually fair; the article explicitly flags its "anecdotal nature." The statistic that "roughly 5.6 percent of men between 30 and 79 have testosterone deficiency" and that "only 1 in 5 of those men, at most, gets treated" is presented without a citation, which is a minor gap. The claim that JD Vance made the "testosterone levels / conservative politics" comment on Rogan's podcast is specific and attributable. No outright factual errors are apparent.

Framing — Uneven

1. "overt fixation on masculinity is by now a familiar feature of the Trump administration" — This is an authorial characterization presented as settled fact rather than attributed to observers or polling data. Readers receive the interpretive conclusion, not the evidence behind it.
2. "the suddenly bulky titans of tech" — "Suddenly bulky" is a loaded phrase implying pharmacological assistance without stating it; the article does not establish that tech figures are actually on T.R.T., making this an innuendo embedded in a feature observation.
3. "an explicitly pro-T administration" — Accurate shorthand, but functions as a political label ("pro-T") that bundles a policy position with cultural coding in the author's voice rather than through attribution.
4. "T is becoming increasingly right-coded" — Again an authorial assertion. The evidence cited (Musk, Thiel, Vance quote) is suggestive but the conclusion is not attributed to a researcher or analyst; it is stated as observed fact.
5. The article's closing paragraphs end on Todd's voice — a man on above-normal doses from an underground lab who has started dating younger women — and his sweeping validation of T.R.T. marketing. This sequencing leaves the reader with the most ideologically charged subject having the last word, a structural framing choice that lends weight to a particular perspective.

Counterpoint: The piece does attribute its strongest claims about medical risks to named specialists (Dubin, Hildebrandt, Selinger), and it consistently provides the nuancing medical voice against cultural overstatement.

Source balance

Ratio: Approximately 5 supportive or personally-positive voices : 3 cautionary/critical : 3 analytical/ambivalent. The 14 anonymous men are nearly all favorable toward T.R.T. in their own cases, which tips the experiential balance further. Notably absent: a voice from the FDA itself (beyond paraphrased actions), a representative from a consumer or patient-safety advocacy group, or a researcher studying harms specifically. Still, the piece includes more critical scientific voices than most popular treatments of this subject.

Omissions

1. Regulatory detail on the April FDA action — The article states the FDA "would broaden the criteria" in April 2025 but does not explain what the formal regulatory mechanism is (proposed rulemaking, guidance, labeling change) or what public-comment opportunities exist. Readers cannot assess how final or reversible the change is.
2. DEA rescheduling process — The panelists called for removing testosterone from Schedule III, but the article does not explain what that rescheduling would require (DEA action, congressional approval, timeline). This is material statutory context for a reader assessing the likelihood of change.
3. Insurance and cost dynamics — Online clinics are mentioned as driving the boom, but the article never addresses whether T.R.T. is covered by insurance under current vs. proposed criteria, which is a significant access variable.
4. Women's T.R.T. — The hormone therapy parallel to women is invoked, but testosterone is also prescribed off-label to women for libido and energy; this is never mentioned, which would complicate the "men's health neglect" framing.
5. Long-term data gap for younger men — The 2023 TRAVERSE trial enrolled men 45–80. Selinger's concern about younger patients is cited but the absence of any long-term safety data for the 35–44 cohort driving prescription growth is not stated explicitly.

What it does well

• Sourcing breadth for a magazine feature: the article integrates historians, regulators, clinicians from multiple specialties, influencers, and ordinary men — "I interviewed 14 men who are on testosterone — getting it from doctors, online clinics and even unregulated underground labs" is a transparent methodological disclosure rarely seen in this genre.
• Historical grounding: the Brown-Séquard origin story and the 60-year prostate-cancer prohibition are told concisely and add genuine explanatory power; "there was almost no testosterone given anywhere in this world" contextualizes the current boom effectively.
• Steelmanning the skeptics: the piece gives the cautionary medical voices (Dubin, Selinger, Hildebrandt) specific, citable findings rather than vague "experts warn" formulations — "six out of the seven online T.R.T. clinics he approached offered him the hormone, despite the fact that he didn't meet criteria" is a concrete undercover finding.
• Internal contradiction surfaced: the Granson quote — "This is the same group of people who go [expletive] over someone who's trans getting hormone therapy, but they're quite all right with some 25-year-old guy that wants to get testosterone" — is a genuine challenge to the administration's ideological coherence that the piece does not suppress.
• Conflict-of-interest disclosure: "most of them urologists (some of whom disclosed ties to telehealth clinics and pharmaceutical companies that make testosterone products)" is noted about the December FDA panel, a transparency marker most features omit.

Rating

Overall: 7/10 — A well-reported, source-rich magazine feature that stumbles on several unattributed interpretive claims and leaves key regulatory and safety-data context underdeveloped.